Riskpilot← Back to searchSign inGet full accessCinclus Pharma AB
ABActiveOrg 5593757684Kungsbron 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20220 employees
Revenue 2024
SEK 6,2M
-29% vs 2023
EBITDA margin
69.4%
-21% vs 2023
Equity ratio
35.9%
Financial strength
Net profit 2024
SEK 0
0 employees
| Revenue | SEK 6,2M | -29% |
| EBITDA | SEK 4,3M | -21% |
| Net profit | SEK 0 | — |
| Total assets | SEK 5,6M | +134% |
| Equity | SEK 2M | +0% |
| Employees | 0 | — |
Legal name
Cinclus Pharma AB
Org number
5593757684
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 april 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska direkt eller indirekt bedriva forskning, utveckling och kommersialisering av läkemedel, förvärv och exploatering av immateriella rättigheter såväl i Sverige som i utlandet, ävensom idka därmed förenlig verksamhet.
Address
Kungsbron 1
Email
finance@cincluspharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 1 462 | 8 743 | 6 171 |
| Staff expenses | — | — | — |
| EBITDA | 64 | 5 452 | 4 283 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | 64 | 5 452 | 4 283 |
| Net financials | 3 | 204 | 8 |
| Profit before tax | 0 | 0 | 0 |
| Tax | −0 | −0 | −0 |
| Net profit | 0 | 0 | 0 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 2 327 | 2 412 | 5 644 |
| Equity | 2 025 | 2 025 | 2 025 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 304 | 387 | 3 619 |
| Total debt | 304 | 387 | 3 619 |
EBITDA margin
69.4%
This company
15.8%
Market median
+339% vs market
20222024
Equity ratio
35.9%
This company
38.2%
Market median
+6% vs market
20222024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20222024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20222024
Asset turnover
1.09×
This company
1.12×
Market median
+3% vs market
20222024
Debt / equity
1.79×
This company
0.62×
Market median
-189% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-04-01 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LG Chief Auditor | Chief Auditor | 2024 | — | — |
SC Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
KL Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Cinclus Pharma Holding AB (publ) | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Cinclus Pharma Holding AB (publ)
Cinclus Pharma AB Board members of Cinclus Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Gustaf Kylberg | Chief Auditor | 0 companies |
| Sven Christer Ahlberg | Chief Executive Officer | 0 companies |
| Karl Leonard Daun | Chief Auditor | 0 companies |
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Marie Helena Levander | Board of Directors | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Viktor Elias Bergman Gullmark | Deputy Board Member | 0 companies |
| Emma Maria Birgitta Wik | Deputy Board Member | 0 companies |
| Andreas Hans Eddie Ottosson | Deputy Board Member | 0 companies |
| Anna Matilda Sjödin | Deputy Board Member | 0 companies |
| Otto Peter Lennart Unge | Board of Directors | 0 companies |
| Kjell Helge Andersson | Board of Directors | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Stig Lennart Hansson | Chairman | 0 companies |
| Anna Carolina Maria Bjarnhagen | Deputy Board Member | 0 companies |
| Nina Rawal | Board of Directors | 0 companies |
| Rolf Stefan Janse | Deputy Board Member | 0 companies |
| Eva Evelina Evelyn Sjöstedt | Deputy Board Member | 0 companies |
| Mari Sinikka Kovaniemi Feldt | Deputy Board Member | 0 companies |
| Olina Kristina Maria Wåhlstedt | Deputy Board Member | 0 companies |
| Wenche Nelly A Rolfsen Sandsborg | Board of Directors | 0 companies |
| Per Anders Roland Öhberg | Board of Directors | 0 companies |
| Torbjörn Mattias Koivisto | Board of Directors | 0 companies |